Drug Profile
INXN 3004
Alternative Names: Anti-CD33 chimeric antigen receptor T cell therapy - PGEN Therapeutics; Anti-CD33-chimeric-antigen-receptor-T-cell-Therapy – Precigen Inc/ZIOPHARM; INXN-3004Latest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator Intrexon Corporation
- Developer Precigen Inc; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 03 Apr 2023 Precigen regains its erxclusive rights from Alaunos Therapeutics
- 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
- 28 Sep 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)